Latest Articles

Publication Date
Common Gynecologic Issues in Patients Post-Kidney Transplantation.

Advances in kidney transplantation have transformed survival and quality of life for women with end-stage renal disease, necessitating a focus on long-term health care for this population. Female kidney transplant …

Published: May 15, 2026, midnight
Bidirectional Mendelian Randomization and Single‑Cell RNA Sequencing Reveal an NK Cell-Mediated Causal Link Between Endometriosis and Endometrial Cancer.

Endometriosis is a chronic estrogen-dependent inflammatory disease that shares epidemiological and pathological features with endometrial cancer. However, the cellular and genetic mechanisms underlying this association remain unclear.

Published: May 15, 2026, midnight
A review on shared genetic architecture of endometriosis and migraine: from pleiotropy to convergent inflammatory pathways.

The comorbidity between endometriosis and migraine has long been recognized clinically, yet a unifying pathophysiological explanation has remained elusive. Traditional models, centered on hormonal fluctuations or secondary inflammation are lacking …

Published: May 15, 2026, midnight
Factors influencing abnormal cleavage of early embryos: time-lapse imaging analysis of 138,178 normally fertilized embryos.

Abnormal cleavage (ABNCL) in early human embryos is a frequent phenomenon associated with impaired developmental competence and reduced reproductive potential. However, the clinical determinants of ABNCL and its subtypes remain …

Published: May 15, 2026, midnight
Karyopharm Therapeutics Reports Q1 2026 Results, Advances Selinexor Phase 3 Trials in Myelofibrosis and Endometrial Cancer - Minichart

Karyopharm Therapeutics Reports Q1 2026 Results, Advances Selinexor Phase 3 Trials in Myelofibrosis and Endometrial Cancer Minichart

Published: May 14, 2026, 4:30 p.m.
Maipl Therapeutics Reports Preclinical Progress for MA-4604, a Novel Oral Non-Hormonal Treatment of Endometriosis - Newswise

Maipl Therapeutics Reports Preclinical Progress for MA-4604, a Novel Oral Non-Hormonal Treatment of Endometriosis Newswise

Published: May 14, 2026, 12:40 p.m.
Karyopharm Therapeut Reports Q1 2026: $35.1M Revenue, $29.2M U.S. Product Sales, Net Loss $22.4M - TradingView

Karyopharm Therapeut Reports Q1 2026: $35.1M Revenue, $29.2M U.S. Product Sales, Net Loss $22.4M TradingView

Published: May 14, 2026, 11:33 a.m.
Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment - PR Newswire

Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment PR Newswire

Published: May 14, 2026, 11:30 a.m.
Press Release: Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment - Moomoo

Press Release: Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment Moomoo

Published: May 14, 2026, 11:30 a.m.
Preliminary Evaluation of Leuprorelin Acetate Microspheres Plus Levonorgestrel-Releasing Intrauterine System in Endometriosis: An Exploratory Study Focusing on BNIP3 and EPAC1 Expression.

This exploratory pilot study aimed to assess the preliminary clinical effects of leuprorelin acetate microspheres for injection [gonadotropin-releasing hormone agonist (GnRH-a)] combined with levonorgestrel-releasing intrauterine system (LNG-IUS) in treating endometriosis …

Published: May 14, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!